Scan beyond IQVIA Holdings and see which peers are also turning guidance upgrades into stronger reported earnings with our curated 35 high quality undervalued stocks.
To own IQVIA Holdings, you mainly need to believe the firm can keep turning its large contract backlog, AI agent deployment and Commercial Solutions demand into consistent earnings, despite pricing pressure in the contract research market. The latest quarter supports that idea, with higher basic and diluted EPS for both the third quarter and the first nine months of 2026.
The raised 2026 revenue guidance matters because it leans on that backlog and R&DS pipeline actually converting into sales rather than sitting in orders. The near term swing factor remains pricing, where competitive bids could cap margins, while the biggest ongoing risk is still debt and refinancing costs if cash generation softens.
The guidance upgrade for 2026 revenue to US$17.35b to US$17.5b is the announcement that ties closest to IQVIA Holdings short term narrative. It points to management having enough visibility across R&DS bookings, Commercial Solutions pipelines and implementation work to frame a tighter range around expected top line delivery.
For you as an investor, the link back to catalysts is straightforward. A higher revenue bar increases the pressure on IQVIA to keep winning outsourced clinical work from emerging biopharma, scale its AI agents with large pharma clients and protect pricing, while still managing leverage so that debt remains comfortably serviceable from operating cash flow.
IQVIA Holdings' narrative projects US$20.8b revenue and US$2.2b earnings by 2029. This implies forecast revenue growth of 6.3% a year and an earnings increase of about US$800m from US$1.4b today.
Uncover why IQVIA Holdings' fair value indicates a 15% potential upside to its current price that could close before any changes in the earnings story.
Some of the most optimistic analysts focus on IQVIA Holdings Commercial Solutions pipeline as the real catalyst. Before this earnings beat and guidance lift, they were already modeling about US$21.8b of revenue and US$2.5b of earnings by 2029. This latest update could either validate that upbeat view or prompt a rethink. Investor opinions can differ sharply, so explore both the cautious consensus and the higher bar set by this bullish camp.
Explore 2 other IQVIA Holdings fair value estimates, including one that suggests as much as 51% upside from the current price.
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
Once you have a view on IQVIA Holdings, it can help to line that thesis up against other opportunities so you can decide where your next dollar of capital works hardest.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com